Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations

Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations

Abstract Background Compared with standard chemotherapy, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations. However, data comparing the efficacies of different EGFR−TKIs, es...

Full description

Bibliographic Details
Main Authors: Naoto Aiko, Tsuneo Shimokawa, Kazuhito Miyazaki, Yuki Misumi, Yoko Agemi, Mari Ishii, Yukiko Nakamura, Takeharu Yamanaka, Hiroaki Okamoto
Format: Article
Language:English
Published: BMC 2018-10-01
Series:BMC Cancer
Subjects:
Brain metastasis
EGFR TKI
Erlotinib
Gefitinib
Lung cancer
NSCLC
Online Access:http://link.springer.com/article/10.1186/s12885-018-4911-7

Internet

http://link.springer.com/article/10.1186/s12885-018-4911-7

Similar Items